Edesa Biotech, Inc.

We are a clinical-stage biopharmaceutical company exploring new ways to treat inflammatory and immune-related diseases.

Our goal is to transform the lives of patients
suffering from acute and chronic diseases


First in Class mAbs

Edesa’s monoclonal antibody candidates have been developed as host-directed therapeutics targeting immune dysregulation


Broad Potential Utility

Our drug candidates are designed to modulate pathways that are implicated across multiple immune-related diseases 

Edesa is a Recipient of Two Federal Strategic Innovation Fund Awards

Acute Respiratory Distress Syndrome (ARDS)

Life-Threatening Respiratory Failure

  • 10% of all admissions to Intensive Care Units (ICU)
  • 40% Mortality in the ICU

Frequent Causes

  • Viral infections like influenza and SARS-CoV2, bacteria, smoke/chemical inhalation and traumatic injury

Promising Clinical Results

  • 84% mortality reduction in critically ill patients. Learn more

Fast Tracked in the U.S.

  • Potential to address an unmet medical need.